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1. Deutsche Zusammenfassung/ German Summary 
Volumenregulation stellt eine überlebenswichtige Eigenschaft aller Zellen dar und 
spielt bei mehreren physiologischen und pathologischen Vorgängen eine Rolle. Der 
volumenregulierte Anionen- Kanal (volume regulated anion channel; VRAC) ist an 
der Volumenregulation, genauer an der regulatorischen Volumenabnahme 
(regulatory volume decrease; RVD), sowie an der Volumenabnahme während der 
Apoptose (apoptotic volume decrease; AVD) beteiligt. Das Protein LRRC8A (leucin 
rich repeat protein 8A) wurde vor kurzem als essenzielle Komponente von VRAC 
identifiziert.  
 
Die Rolle von LRRC8A bei der RVD von HeLa Zellen konnte in der vorliegenden 
Arbeit mit Methoden der Durchflusszytometrie bestätigt werden. Das 
Herunterregulieren der Expression von LRRC8A durch RNA Interferenz und die 
pharmakologische VRAC Hemmung führten zu einer verzögerten RVD, hoben aber 
die RVD nicht auf. Es zeigte sich, dass andere Transportmechanismen, wie der K+-
Cl- Symporter (KCC), eine entscheidende Rolle spielen. Trotz der universellen 
Expression des LRRC8A Proteins, trägt dieses in verschiedenen Zelltypen in 
unterschiedlichem Maße zur RVD bei. In der vorliegenden Arbeit sollte auch geklärt 
werden, ob Ca2+ aktivierte Chlorid-Kanäle der TMEM16 Familie an der RVD beteiligt 
sind. Die Ca2+ aktivierten Chlorid-Kanäle TMEM16F- und TMEM16K-Proteine hatten 
keinen direkten Effekt auf die RVD von HeLa Zellen. 
 
Auf die Proliferation von HeLa Zellen hatte die Expression des LRRC8A Proteins 
keinen Effekt. Das Herunterregulieren der Expression von LRRC8A und die 
pharmakologische Hemmung von VRAC konnten die AVD nicht inhibieren. Die 
vorliegenden Daten deuten darauf hin, dass KCC und TMEM16F an der AVD 
beteiligt sind. 
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2. Introduction  
2.1 Cell volume regulation 
Cell volume regulation is an extremely important cellular function, as it is involved in a 
variety of physiological and pathological procedures, such as epithelial transport, 
regulation of metabolism, proliferation, differentiation, migration, necrosis and 
apoptosis. Water can easily pass through the cell membrane via water channels 
called aquaporins (AQP). The cell membrane is much less permeable to ions ; 
sodium (Na+), potassium (K+), calcium (Ca2+) and chloride (Cl-) ions can only pass 
through ion channels and ion pumps, whereas large negatively charged polyvalent 
macromolecules are practically confined in the intracellular compartment. Thus, a 
change of the extracellular osmolality leads to an initial rapid influx or efflux of water 
because of the osmotic dysequilibrium of water across the cell membrane. When the 
cell is exposed to decreased extracellular osmolality, water rapidly enters through the 
plasma membrane and causes cell swelling and subsequent activation of channels or 
transporters, which release K+, Cl- and small organic osmolytes from the cell. Due to 
osmotic pressure water molecules are obliged to follow, leading to decrease of the 
cell volume, a process called regulatory volume decrease (RVD) (Wehner et al. 
2003) (Fig.1).  
2.2 Regulatory volume decrease 
RVD is mediated through swelling activated Cl- and K+ channels as well as K+-Cl- 
cotransporters. Before molecular identification of these channels, the ion efflux 
(current) had been described phenomenologically by electrophysiological methods. 
Further research could then correlate the swelling activated K+ efflux [K+ current, 
IK+(VOL)] with Ca
2+ activated K+ channels of large (BK), intermediate (IK) and , to 
lesser extent, small conductance (SK), as well as with voltage gated K+ channels 
(Kv1, Kv4), tandem pore domain (2P-4TM) and KCNQ K+ channels (Stutzin und 
Hoffmann 2006). The K+-Cl- cotransporters (KCC), a subfamily consisting of four 
homologues, has been found to be the mediator of the swelling activated coupled K+ 
and Cl- efflux (Dunham et al. 1980; Lauf und Adragna 2000). On the contrary, things 
turned out to be much more complicated regarding the swelling activated Cl- current 
[ICl(swell)]. Even though this current could be recorded as early as 1988 (Hazama und 
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Okada 1988) and the biophysical properties of its channel could be characterized 
extensively (Hoffmann et al. 2009), its molecular identity had been elusive for almost 
thirty years. This channel is known as volume regulated anion channel (VRAC) but, 
because of its properties, has also received the names volume sensitive outwardly 
rectifying anion channel (VSOR) or volume sensitive organic osmolyte and anion 
channel (VSOAC). 
 
 
 
Figure 1: Mechanism of regulatory volume decrease. Hypotonic challenge osmotically drives 
H2O into the cell, causing it to swell. After channel or transporter activation, K
+, Cl- and small 
organic osmolytes are released from the cell, followed by H2O.  
2.3 VRAC characteristics and identification 
Although cell swelling is the main mechanism of VRAC activation, it has been 
demonstrated that a reduction in the intracellular ionic strength also leads to VRAC 
activation even under isovolumetric conditions (Nilius et al. 1998). The VRAC current 
has been described as outwardly rectifying, meaning that the channel more easily 
transfers anions in the outward direction (towards the cytosolic compartment) than in 
the inward direction (out of the cell). VRAC can also transfer other halide ions except 
Cl-, like I-, F- and Br-, as well as much larger amino acids, e.g. taurine, glutamate and 
aspartate. VRAC exhibits a different permeability for each of those molecules, 
following the sequence I-> Br-> F-> taurine> glutamate> aspartate (Nilius et al. 1994). 
The pharmacological properties of VRAC have been tested with a wide variety of 
substances; some of its inhibitors are the classic Cl- channels inhibitors 4,4’-
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diisothiocy-ano-2,2’-stilbenedisulfonic acid (DIDS), 5-nitro-2-(3-phenylpropyl-amino) 
benzoic acid (NPPB), and niflumic acid, anti-estrogens, such as tamoxifen, the novel 
group of acidic di-aryl-ureas and 4-(2-butyl-6,7-dichlor-2-cyclopentyl-indan-1-on-5-yl)-
oxybutyric acid (DCPIB) (Hélix et al. 2003; Han et al. 2014). Nevertheless, none of 
them has been shown to be potent and perfectly selective, a fact which has also 
impeded the identification of VRAC. 
 
Several proteins have been proposed as potential VRAC candidates over the last 
years, more recently including TMEM16A, TMEM16F and bestrophins. Nevertheless, 
none of them exhibited all of the VRAC properties (Pedersen et al. 2015). The elusive 
channel seems to have been identified in 2014 by two independent groups. Qiu et al. 
(Qiu et al. 2014) and Voss et al. (Voss et al. 2014) have simultaneously reported that 
the leucin rich repeat protein 8A (LRRC8A)/ SWELL 1 is an essential component of 
VRAC. LRRC8 is a protein family consisting of five members, LRRC8A-LRRC8E, 
which was first described in a girl with agammaglobulinemia (Sawada et al. 2003). 
Both groups claim that LRRC8A is a broadly expressed cell membrane protein which 
is indispensable for VRAC currents. The other four isoforms are thought to be 
dispensable, but the generation of VRAC current requires at least the presence of 
one of them in the cell in combination with LRRC8A (Qiu et al. 2014; Voss et al. 
2014). LRRC8A mediated currents were shown to be involved in RVD in HeLa cells 
(Qiu et al. 2014). A sequence resemblance to the family of pannexins has been 
observed, possibly suggesting an organization of LRRC8 subunits in hexamers, as 
pannexins (Abascal und Zardoya 2012).  
2.4 Role of VRAC in apoptosis 
Apoptosis, a form of programmed cell death, is a tightly regulated complex 
procedure, which plays an important role in physiological and pathological processes, 
such as organ development, cell turnover and cancer (Kerr et al. 1972). Two major 
apoptotic pathways have been identified: the extrinsic-death receptor pathway and 
the intrinsic-mitochondrial pathway. They both have the subsequent activation of the 
executioner caspase 3 in common, which then leads to protease and endonuclease 
activation, resulting to chromatin and cytoplasmic condensation, DNA fragmentation, 
cytoskeleton degradation and apoptotic bodies formation. The subsequent 
phagocytosis of the apoptotic bodies effectively eliminates the cell residues without 
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causing an inflammatory response (Elmore 2007). A morphological hallmark of 
apoptosis is an initial cell shrinkage, called apoptotic volume decrease (AVD). AVD 
is, similar to RVD, the result of K+ and Cl- efflux. Apoptotic stimuli, apart from osmotic 
swelling, have been shown to activate the VRAC, leading to Cl-  efflux and AVD in 
many different cell types (Okada et al. 2006). VRAC inhibition has been reported to 
abolish AVD after pharmacological induction of apoptosis and, further, to inhibit 
apoptosis. From this assays was concluded that AVD is a prerequisite for apoptosis 
(Maeno et al. 2000).  
 
Furthermore, cisplatin induced apoptosis was associated with enhanced VRAC 
activity in cancer cells (Okada et al. 2006; Cai et al. 2015) and consecutive studies 
reported that acquired cisplatin resistance in cancer cells is linked to impaired VRAC 
activity (Lee et al. 2007; Sørensen et al. 2014). 
2.5 Role of TMEM16 in RVD and apoptosis 
TMEM16 is a novel family of 10 proteins, also known as anoctamins. Whereas 
TMEM16A and TMEM16B have been functionally characterized as Ca2+ activated Cl- 
channels (CaCC) with roles in transepithelial ion transport, smooth muscle 
contraction, olfaction, phototransduction, pain perception and cell proliferation, the 
function of the other members still remains an object of intensive research (Tian et al. 
2012; Picollo et al. 2015). TMEM16F has been described to act as a CaCC 
(Schreiber et al. 2010), as a cation channel (Yang et al. 2012) and as a phospholipid 
scramblase (Suzuki et al. 2010), transporting phospholipids between the two leaflets 
of the cell membrane. To date it remains unclear how TMEM16F can combine those 
heterogenous features.  
An uneven distribution of phospholipids in the two layers of the cell membrane is 
essential for cell homeostasis. The phospholipid phosphatidylserine also shows an 
uneven distribution, being located only on the inner leaflet of the cell membrane in 
resting cells (Verhoven 1995). Loss of this asymmetry with appearance of 
phosphatidylserine on the outer membrane activates the haemostasis cascade 
(Lentz 2003) and the apoptotic pathway and is also essential for the phagocytic 
recognition of apoptotic cells by macrophages (Fadok et al. 2001). The activity of 
TMEM16F as a scramblase and a channel has been shown to contribute to 
haemostasis as well as to apoptosis (Yang et al. 2012; Kmit et al. 2013). 
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Recently TMEM16K has been reported to augment RVD in macrophages (Hammer 
et al. 2015). 
2.6 Purposes of the present study 
VRAC is involved in the processes of regulatory and apoptotic volume decrease, thus 
playing an important role in cell volume regulation and apoptosis. VRAC has been 
chosen as the topic of this study because of its significance for a number of 
pathological conditions, including cancer and acquired resistance to 
chemotherapeutics, and, thus, for its clinical importance. The molecular identity of 
VRAC has been unknown for decades and recently Qiu et al. and Voss et al. claimed 
to have identified the protein LRRC8A as its essential component. The objective of 
this study was to confirm or disprove the proposed role for LRRC8A in the RVD. The 
RVD was principally examined in HeLa cells, one of the cell models used by the two 
groups mentioned above, and further in BHY cells, after VRAC inhibition or LRRC8A 
knockdown. A further goal of this study was to investigate the role of LRRC8A/ VRAC 
in apoptosis. In this case, apoptosis was induced chemically after pharmacological 
VRAC inhibition or LRRC8A knockdown and the apoptosis rate was assessed with 
caspase 3 assays. Additionally, the role of the TMEM16 proteins in RVD and 
apoptosis was examined using the same methodology.  
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3. Materials and methods 
3.1 Cell culture 
The cell lines used were the cervical adenocarcinoma cell line HeLa, provided by 
Prof. Dr. Karin Hoppe-Seyler (German Cancer Research Center, Heidelberg) and the 
oral squeamous cell carcinoma cell line BHY, provided by Dr. Christian Ruiz (Institute 
of Pathology, University Clinic, Basel). HeLa cells were cultured in Dulbecco’s 
modified Eagle medium containing 1 g/L D-glucose, L-glutamine and pyruvate and 
BHY cells were cultured in OptiMEM. Both were supplemented with 10% fetal bovine 
serum, 100 U/ mL penicillin and 100 μg/ mL streptomycin (all from Gibco, Life 
Technologies, Saint Louis, MI, USA). HeLa were passaged every 4 to 5 days and 
BHY every 7 days, both were cultured in T75 wells (Cellstar, Greiner Bio-One, 
Frickenhausen). 
3.2 RNA interference 
A useful method for protein function studies is carrying out experiments after 
eliminating the expression of the responsible gene, a procedure called gene 
knockdown. The product of gene transcription is the messenger RNA (mRNA), which 
is then translated into the protein. By inserting a synthetic RNA molecule into the cell 
with a sequence complementary to the mRNA of interest, the two molecules bind 
together and are degradated, thus hindering translation and protein expression. This 
small RNA molecule is called small interfering RNA (siRNA), its insertion into the cell 
is called transfection and the whole process is called RNA interference. In order to 
insert the siRNA into the cell through the, under normal conditions impermeable for 
nucleic acids, plasma membrane, two methods of transfection were used; lipofection 
and electroporation. For lipofection the siRNA was embedded into vesicles made of a 
phospholipid bilayer, which could fuse with the cell membrane releasing their content 
into the intracellular compartment. For electroporation a strong electric field was used 
to create short-lived small water filled ‘holes’, through which the hydrophilic siRNA 
could pass the membrane.  
 
For the transfection with siAQP3 6x106 cells were electroporated (voltage: 1005 V, 
width: 35 ms, pulses: 2) with 1 µL siRNA in 100 µL resuspension buffer R (Neon 
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Transfection System and 100 µL Neon Kit, Invitrogen, Life Technologies). The cells 
were then resuspended in medium without antibiotics. All other transfections were 
performed with lipofection using Lipofectamine 3000 (Invitrogen, Life Technologies), 
according to manufacturer’s protocols. The final siRNA concentration in the well was 
17,6 nM, the final Lipofectamin 3000 concentration was 0,16%. The cells had been 
seeded 12-24 hours prior to transfection in medium without antibiotics. 
 
After transfection the cells were incubated for 24-72 hours before being used for 
experiments, according to the time point of the best protein suppression in 
immunoblotting. For the transfection with siTMEM16F, siTMEM16K and siAQP3 we 
used a mixture of two different siRNAs in equimolar concentration, which had been 
previously shown in immunoblotting to suppress the protein expression better 
compared to a single siRNA. All siRNAs used were purchased from Ambion, Life 
Technologies. Their sequence is shown in table 1. 
 
Table 1: Used siRNAs and their sequence.  
siRNA Sequence 5’3’ Product type 
Sicontrol s:   UAACGACGCGACGACGUAAtt 
as: UUACGUCGUCGCGUCGUUAtt  
 
Silencer select 
siLRRC8A s:  CCAAGCUCAUCGUCCUCAAtt 
as: UUGAGGACGAUGAGCUUGGtg 
Silencer select 
siTMEM16F a. s:   CCUGAUAUUGGUGGCAAGAUCAUAA 
    as: UUAUGAUCUU GCCACCAAUA UCAGG 
b. s:  CCUCCAUCAUCAGCUUUAUAAUUAU 
    as: AUAAUUAUAA AGCUGAUGAUGGAGG 
Stealth siRNA 
siTMEM16K a. s:   CGAUGAGUGUUAUAUCUGU 
    as:  ACAGAUAUAA CACUCAUCG 
b. s:  GAAUCGUCUCUAUCGAUAU 
    as: AUAUCGAUAG AGACGAUUC  
Silencer select  
siAQP3  a. s:   GGACACUUGGAUAUGAUCA 
    as: UGAUCAUAUCCAAGUGUCC 
b. s:   CCGGCAUCUUUGCUACCUA 
    as: UAGGUAGCAA AGAUGCCGG 
Silencer select 
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3.3 RNA isolation and reverse transcription-PCR (RT-PCR) 
Total RNA was isolated from HeLa cells using NucleoSpin RNA Kit (Macherey-Nagel 
GmbH, Düren). Complementary DNA (cDNA) was prepared in a total volume of 50 
µl. Total RNA (1 µg) was denaturated at 70°C for 5 min and was hybridized to 
random primers (500 ng) at 21°C for 10 min. Reverse transcription occurred at 40°C 
for 1 hour in the presence of 200 Moloney murine leukemia virus reverse 
transcriptase (UM-MLV RT), 40 U of RNasin ribonuclease inhibitor, 500 μM dNTPs, 
in M-MLV RT 5X buffer containing 50mM Tris-HCl (pH 8.3), 75mM KCl, 3mM MgCl2 
and 10mM DTT. Finally, the RT was inactivated at 70 C for 15 min. PCR was 
performed in a total volume of 20 μL containing 0,5 μL of the reverse transcription 
reaction, 0,2 mM dNTPs, 1 μL of each primer (10 µM, Eurofins MWG Operon, 
Huntsville, AL, USA) and 0,5 U Go Taq G2 DNA polymerase and Go Taq reaction 
buffer with 1,5 mM MgCl2. PCR consisted of a denaturizing step of 2 min at 95 °C 
followed by 30 cycles of 30 s in 95 °C, 30 s in 58 °C and 1 min in 72 °C. Unless 
stated otherwise, everything was purchased from Promega (Madison, WI, USA). The 
primers used for PCR are listed in table 2.  
 
 
Table 2: Primers used in the RT-PCR. 
Target 
 
Sequence(5’3’) Annealing 
temperature 
Size 
(bp) 
TMEM16A s:   CGACTACGTGTACATTTTCCG 
as: GATTCCGATGTCTTTGGCTC 
62 °C 
60 °C 
445 
TMEM16B s:   GTCTCAAGATGCCAGGTCCC 
as: CTGCCTCCTGCTTTGATCTC 
64 °C 
62 °C 
553 
TMEM16C s:   CTTCCCTCTTCCAGTCAAC 
as: AAACATGATATCGGGGCTTG 
58 °C 
58 °C 
461 
TMEM16D s:   CGGAAGATTTACAGGACACCC 
as: GATAACAGAGAGAATTCCAATGC 
64 °C 
64 °C 
503 
TMEM16E s:   GAATGGGACCTGGTGGAC 
as: GAGTTTGTCCGAGCTTTTCG 
58 °C 
60 °C 
713 
TMEM16F 
 
s:   GGAGTTTTGGAAGCGACGC 
as: GTATTTCTGGATTGGGTCTG 
60 °C 
58 °C 
325 
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TMEM16G s:    CTCGGGAGTGACAACCAGG 
as:  CAAAGTGGGCACATCTCGAAG 
62 °C 
64 °C 
470 
TMEM16H s:   GGAGGACCAGCCAATCATC 
as: TCCATGTCATTGAGCCAG 
60 °C 
54 °C 
705 
TMEM16I s:   GCAGCCAGTTGATGAAATC 
as: GCTGCGTAGGGTAGGAGTGC 
56 °C 
62 °C 
472 
TMEM16K s :  GTGAAGAGGAAGGTGCAGG  
as: GCCACTGCGAAACTGAGAAG 
60 °C 
62 °C 
769 
LRRC8A s:   CGCAGATAGCAGAGCCATCC 
as: CATCTTGCTGAAGGCCGGC 
64 °C 
62 °C 
603 
 
The PCR products were separated using a 2% agarose (Biozym Scientific, Hessisch 
Oldendorf) gel electrophoresis. The RNA isolation, reverse transcription and PCR 
were performed at least in triplicate.  
The mRNA expression levels of the examined proteins were normalized to GAPDH 
using the program MetaMorph (Universal Imaging Corporation, New York, USA).  
3.4 Proliferation assays 
HeLa cells were seeded in a density of 10.000 cells/ ml DMEM+10% FBS well in 24-
well-plates (TPP, Trasadingen, Switzerland). The transfection with siLRRC8A was 
performed 12 hours later. The cells were treated with the compounds DMSO 0,1%, 
tamoxifen 1 µM and 10 µM (both from Sigma-Aldrich) and T16inh-A01 10 µM (Tocris 
Bioscience, Bristol, UK). In the compound treated group the initial media was 
removed and replaced with media containing the compound in the desired 
concentration 12 hours post seeding. A change of media was performed in the 
compound group every 24 hours. The cell numbers/ well were count in a triplicate for 
seven days, starting 24 hours post seeding (day 1). For counting, cells were 
detached from the well as following: the medium was removed; after a washing step 
with Dulbecco’s phosphate-buffered saline containing CaCl2 and MgCl2 (DPBS
+) 
(Gibco), cells were incubated with 1 mM EDTA-DPBS for 5 minutes. EDTA 
(ethylenediaminetetraacetic acid) was also purchased from Gibco.  Supernatant was 
removed and cells were incubated with 0,5 ml trypsin (Gibco). Five minutes later, 
DMEM+10% FBS (0,5 ml) was added and cells were transferred for measurement to 
a 1,5 ml tube (Eppendorf, Wesseling-Berzdorf). 
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3.5 Flow cytometry  
Cell volume, number and viability were measured with flow cytometry using Casy 
Model TT Cell Counter and Analyser (Roche, Indianapolis, Indiana, USA) relying on 
electronic pulse area analysis and on electric current exclusion principle respectively. 
According to manufacturer’s instructions the cell sample was diluted in an isotonic 
saline solution (Casy Ton, Roche) and was aspirated with a constant speed into a 
capillary with a narrow measuring pore. An electrical field was applied into the 
measuring pore. Generally the viable cells passing through the pore have an intact 
cell membrane, which generates an increased resistance, compared to the 
electrolyte solution. This increased resistance is detected by the flow cytometer and 
serves as a dimension for cell size. On the contrary, dead cells have a permeable to 
electrical current membrane, but an impermeable nucleus, leading to the recording of 
smaller resistance, which is interpreted as a smaller cell diameter (Fig. 2).  
 
Initially we examined the distribution of cells growing exponentially and the 
distribution of cells after induction of cell death. In this manner it was possible to 
identify the size of the nucleus and set it as a threshold to differentiate between 
viable and dead cells in the upcoming measurements (Fig. 3). The particles with a 
very small size were interpreted as debris. We repeated this procedure for HeLa and 
BHY cells and created two different set-ups for the upcoming experiments. The size 
of HeLa and BHY cells was found to be between 15-20 µm, so the 150 µm capillary 
was selected for the experiments, according to manufacturer’s instructions. For the 
proliferation experiments we adjusted the dilution factor (volume of cell suspension/ 
volume of CASY ton) in such a way, that the total cell count was higher than 1000 pro 
measurement to guarantee statistically reliable results. 
 
Experiments regarding cell proliferation were carried out at room temperature (RT) 
using filtered (Minisart filter 0,45 µm, Sartorius stedim, Göttingen) Casy Ton. The 
experiments concerning the RVD were carried out at 37°C in Ringer’s solution (290 
mOsm/ kg), hypotonic 35% Ringer’ s solution (depletion of 50 mM NaCl, 210 mOsm/ 
kg) and isotonic Ringer’s solution (50 mM NaCl replaced with mannitol, 290 mOsm/ 
kg) (Table 3). All solutions apart from Casy Ton were initially filtered with a Nalgene 
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Rapid-Flow filter (Thermo-Fischer Scientific, Waltham, MA USA). Before use they 
were additionally filtered with a 0,45 µm Minisart filter.  
 
 
 
 
 
Figure 2:  CASY cell counter: electric current exclusion principle. A1. Dead cells have a cell 
membrane permeable to the electrical current. The signal detected represents the size of the 
nucleus. A2. Living cells have an intact membrane which is impermeable to the electrical 
current. The detected signal refers to the cell size.  
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Figure 3: Casy cell counter. Typical size distribution of HeLa cells growing exponentially. 
 
 
Table 3: Used solutions. Molar concentrations of compounds given in mmol/ L. The pH of the 
solutions was corrected to be 7,4 with NaOH or HCl prior to their use.  
 Ringer’s Ringer’s -50mM 
NaCl/ isotonic 
Ringer’s -50 
mM NaCl/ 
hypotonic 35% 
NaCl 145  95 95 
KH2PO4 0,4 0,4 0,4 
K2HPO4.3 H2O 1,6 1,6 1,6 
Glucose 5 5 5 
MgCl2.6H2O 1 1 1 
Ca-Gluconate.1H2O 1,3 1,3 1,3 
Mannitol  100  
Osmolality (mOsm/ kg) 290  290 210 
 
3.6 RVD experiments 
Initially the size of polystyrene beads (20 µm, Polysciences Inc., Warrington, PA, 
USA) was measured in Ringer’s and Ringer’s -50 mM hypotonic 35% solution. In this 
way it could be ruled out that the different tonicity influences the recorded size (data 
not shown).  
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3.6.1 Seeding density and incubation time 
For RVD experiments in cells treated with siRNA against LRRC8A, HeLa cells were 
seeded in 12-well-plates in a density of 50.000 cells/ml DMEM+10%FBS and BHY 
cells in 12-well-plates in a density of 80.000/ ml OptiMEM+10% FBS. They were 
transfected after 12 hours with siRNA against LRRC8A. The RVD experiment was 
carried out 60 hours post transfection. For measurements of RVD in TMEM16F 
downregulated cells, HeLa cells were seeded at a density of 80.000 cells/ ml 
DMEM+10%FBS and were transfected with siRNA against TMEM16F 24 hours later. 
The experiment was carried out 24 hours post transfection. For RVD in TMEM16K 
downregulated cells, HeLa cells were seeded at a density of 80.000/ ml 
DMEM+10%FBS and were transfected with siRNA against TMEM16K 12 hours later. 
The experiment was carried out 36 hours post transfection.  
 
For RVD experiments in cells treated with siRNA against AQP3 HeLa cells were 
electroporated, seeded at a density of 50.000/ ml DMEM+10%FBS and examined 72 
hours post transfection. For all the experiments referred above, a control group of 
cells was transfected with scrambled control siRNA, all other conditions being the 
same. For all experiments with compounds, HeLa cells were seeded at a density of 
40.000/ ml DMEM+10%FBS and the experiments were carried out 72 hours later. As 
stated under 3.2., a different incubation time with siRNA was applied, according to 
the time point of the best protein suppression in immunoblotting. The cells ware 
seeded at different densities, in order to be about 80%-90% confluent at the time of 
the experiment. 
3.6.2 Experimental protocol 
The cells were detached from the well as following: after washing with DPBS+, they 
were incubated with 300 µl accutase (Invitrogen) for 5 minutes. Then 700 µl fresh 
media was added and the cells were transferred to 1,5 ml tube. BHY cells were 
additionally incubated with 1 mM DPBS-EDTA for 5 minutes before adding accutase. 
After centrifugation (400 RCF, 3 minutes, 37°C) the supernatant was removed and 
500 µl Ringer’s solution was added. After incubation of 10 minutes at 37°C the first 
measurement was performed with Casy cell counter. The sample was centrifuged 
again under same conditions. After removing the supernatant, 475 µL of warm (37°C) 
Ringer’s, Ringer’s hypotonic 35% or Ringer’s isotonic solution were added at time 
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point zero (t=0). Measurements were then carried out at the time points of 0,5 ,1,5 , 
2,5…10,5 minutes. Between the measurements the cell sample was kept in water 
bath at 37°C. 
3.6.3 Compounds 
The compounds used for RVD experiments were: tamoxifen, R-(+)-DIOA, DMSO, NS 
8593, tetraethylammonium (TEA), staurosporin (all from Sigma Aldrich), wortmannin 
(Invivo Gen, San Diego, CA, USA), T16Ainh-A01, SKF 96365 and GSK 650394 (all 
three from Tocris Bioscience), NS 3728 (Neurosearch, Hellerup, Denmark) and 
bariumchloride dehydrate (Merck Millipore, Billerica, MA, USA). All compounds were 
dissolved in DMSO and this was used as a control. The DMSO concentration in 
Ringer’s/ Ringer’s hypotonic 35%/ Ringer’s isotonic solution did not exceed 0,4% v/v, 
which had no effect on the RVD compared to untreated cells (data not shown). With 
the exception of staurosporin, all experiments in presence of compounds were 
carried out using Ringer’s, Ringer’s hypotonic 35% and Ringer’s isotonic solution 
containing the compound in the desired concentration. Staurosporin was only added 
in the wells. 
3.6.4 Experiments with staurosporin  
The bacterial alkaloid staurosporin was used to induce apoptosis. LRRC8A and 
TMEM16F downregulated HeLa cells were preincubated for four hours with 
staurosporin 1 µM before performing the RVD experiments. For the experiments with 
staurosporin and RDIOA or NS 3728, HeLa cells were preincubated with RDIOA 50 
µM or NS 3728 10 µM for 30 minutes and then further incubated for four hours with 
media containing RDIOA 50 µM or NS 3728 10 µM and additionally staurosporin 1 
µM.  
3.7 Data analysis and statistics 
The recorded values from Casy cell counter were imported into a personal computer 
using software Casy Excel 2.4. (Roche). The volume values at t=0,5 up to 10,5’ for 
every single experiment with Ringer’s hypotonic 35% solution were later imported 
into the program OriginPro 8.0 (OriginLab Corp. Northampton, MA, USA) and were 
further analyzed and plotted against time. In order to compare the results of the 
various experiments, the RVD curves were fitted into a single exponential decay 
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function (y=y0+A
 -R
0
x; y being the volume at any given time point x, y0 being the initial 
volume at the time point =0,5’ after adding Ringer’s hypotonic 35% and R0 being the 
exponential decay constant). The values y0, A and R0 were calculated for every 
experiment. We used following criteria to compare the RVD in the various 
experiments:  
a. cell volume at t=2,5’ after adding Ringer’s hypotonic 35%  
b. R0  
c. time required for the half maximal RVD. 
The half maximal RVD was calculated by subtracting the volume at t=10,5’ from the 
volume at t=0,5’, dividing by 2 and adding the quotient to the volume at t=10,5’. By 
replacing y with this value in the equation y=y0+A
 R
0
x , we can calculate x (y0, A and 
R0 had already been calculated).  
For statistical analysis paired or unpaired Student’s t-test was used with a 
significance level of 0,05.  
3.8 Caspase 3 assay 
3.8.1 Method 
To study apoptosis a caspase activation assay was used. The NucView 488 
Caspase-3 Assay Kit was purchased from Biotium (Hayward, CA, USA). The 
NucView™ 488 Caspase-3 Substrate consists of the DNA-dye NucView 488 
attached to the amino acid sequence Asp-Glu-Val-Asp (DEVD), which is cleaved by 
activated caspase 3 (Antczak et al. 2009). The attachment of the positively charged 
DNA dye to the negatively charged peptide leads to electroneutrality and thus, to cell 
membrane permeability and, at the same time, inactivates the DNA binding ability of 
the compound. Though enzymatic cleavage by the activated caspase 3 in apoptotic 
cells the positively charged DNA dye is released, it enters the nucleus, binds the 
DNA and fluoresces upon excitement at 488 nm (Skommer et al. 2014) 
3.8.2 Experimental protocol 
For the NS 3728 and RDIOA experiment HeLa cells were seeded at a density of 
100.000/ml DMEM+10%FBS in 12 well plates with fibronectin (PromoCell, 
Heidelberg) coated 18 mm diameter cover glasses (Hartenstein, Germany). 24 hours 
post seeding the cells were incubated with NS 3728 10 µM or RDIOA 50 µM or 
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DMSO 0,5% v/v for 30 minutes. The cover glass was attached then to a chamber 
using silicone (Bayer, Leverkusen) and 200 µl DMEM+10% FBS containing caspase 
3 substrate 2 µM, staurosporin 1 µM or DMSO 0,5% v/v (control for staurosporin) 
and, additionally, NS 3728 10 µM or RDIOA 50 µM or DMSO 0,1% v/v (control for 
RDIOA or NS 3728). For the experiment in LRRC8A deficient cells, HeLa cells were 
seeded at a density of 20.000/ ml DMEM+10% FBS and transfected with siLRRC8A 
and control siRNA 12 hours later using Lipofectamin 3000. The experiment was 
carried out sixty hours post transfection. For the experiment in TMEM16F 
downregulated cells, HeLa cells were seeded in a density of 80.000/ ml DMEM+10% 
FBS and transfected with siTMEM16F and control siRNA 12 hours later. The 
experiment was carried out 24 hours post transfection. The cover glass was attached 
to a chamber using silicone and 200 µL DMEM+10% FBS containing caspase 3 
substrate 2 µM, staurosporin 1 µM or DMSO 0,5% v/v. 
 
The cover glasses were kept in wet chamber in the incubator (37°C, 5% CO2) until 
images were acquired six hours later with an Axiovert 200 M microscope (Zeiss, 
Göttingen) and an 20x objective. The excitation wavelength was 488 nm and the 
exposure time 200 msec. The emission fluorescence was measured at 520 nm. Four 
to five image fields were collected pro cover glass. Data were acquired using the 
software AxioVision SE64 Rel. 4.8 (Zeiss). The number of total and fluorescent cells 
was counted manually using the software ImageJ (National Institutes of Health, 
USA).The result was given as the percentage of the fluorescent to the total cells. For 
every experiment at least four cover glasses were used. 
3.9 Immunoblotting 
3.9.1 Method 
Immunoblotting is a method for detecting proteins in tissue or cell samples. After cell 
lysis and centrifugation steps, the proteins are separated with electrophoresis 
according to their molecular weight. Next, the proteins are transferred onto a special 
membrane, where they are accessible to the primary antibody. This antibody is 
designed especially for the protein of interest and binds it with high affinity. A 
secondary antibody, tagged with the enzyme horseradish peroxidase (HRP), is then 
applied and binds specifically to the primary antibody. Subsequently a 
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chemiluminescent agent is added and it is cleaved by the HRP producing 
luminescence, which is proportionate to the amount of the protein contained in the 
sample. The luminescence is recorded on a photographic film, where the proteins are 
to been seen as stained bands. The procedure is performed also for a housekeeping 
protein, e.g. GAPDH, which is known to be expressed in stable levels in the cell and 
serves as control. The bands are then compared to proteins with known molecular 
weight, which are used as a ‘’ladder’’ in the electrophoresis. All immunoblotting 
experiments were kindly performed by the PhD student Ms. Podchanart 
Wanitchakool. 
3.9.2 Experimental protocol 
Protein was isolated from HeLa and BHY cells using 1% of Nonidet P-40 (Sigma-
Aldrich), separated with a 8,5-12,5 % sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred onto a polyvinylidene fluoride (PVDF) 
membrane (Immobilon-PSQ Membrane, Merck Millipore, Billerica, MA, USA ). The 
blots were developed with SuperSignal West pico Chemiluminescent Substrate 
(ThermoFischer Scientific, Waltham, MA, USA). The antibodies used for 
immunoblotting and the conditions for the experiments are shown in table 4.  
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Table 4: Antibodies used for immunoblotting 
Protein First antibody Second antibody 
LRRC8A rabbit anti-LRRC8A 
1:1000, Sigma Aldrich 
in 0,25 % BSA/ TBST  
at 4°C overnight  
HRP-conjugated goat anti-
rabbit, 1:10.000, Acris, 
Hiddenhausen)  
in 1% NFM/ TBST 
at room temperature (RT) 
for 2 hours  
AQP3 goat anti-AQP3  
1:250, Santa Cruz 
in 1% BSA/ TBST 
at 4°C overnight 
the HRP-conjugated donkey 
anti goat IgG  
1:2000, Santa Cruz 
 in 3% NFM/ TBST  
at RT for one hour 
TMEM16A rabbit anti-DOG1/ TMEM16A 
1:1000 Novus Biologicals,      
Cambridge, UK 
 in 1% NFM/TBST 
 at 4°C overnight 
HRP-conjugated goat anti-
rabbit  
1:10.000,  Acris 
in 1% NFM/ TBST  
at RT for 2 hours 
TMEM16F rabbit anti-TMEM16F  
1:500, Davids Biotechnologie 
Regensburg 
in 1% NFM/ TBST  
at 4°C overnight 
HRP-conjugated goat anti-
rabbit  
1:10.000, Acris 
in 1% NFM/ TBST  
at RT for 2 hours 
TMEM16K rabbit anti-TMEM16K 
1:1000, Aviva, San Diego, 
CA, USA 
in 5% NFM/ PBST  
at 4°C overnight 
HRP-conjugated goat anti-
rabbit 
1:10.000, Acris 
in 5% NFM/ PBST 
at room temperature for two 
hours 
GAPDH rabbit anti-GAPDH  
(FL-335:sc-25778) 
1:3000, Santa Cruz 
in 5% NFM/ PBST  
at 4°C overnight 
HRP-conjugated goat anti-
rabbit   
1:10.000, Acris 
in 1% NFM/ PBST  
at RT for 2 hours 
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4. Results 
4.1 TMEM16 and LRRC8A mRNA expression in HeLa cells  
In order to examine the expression of TMEM16 and LRRC8A mRNA in HeLa cells we 
performed a RT-PCR. Figure 4 shows an expression of TMEM16F and TMEM16K 
and a weaker expression of TMEM16D, TMEM16H and LRRC8A. 
 
Figure 4: A. Agarose-gel electrophoresis of the reverse transcription products in HeLa cells. 
A. 100-base-pair (bp) DNA ladder was used as a marker (M), arrows indicate the PCR 
product length in base pairs (bp). RT (-) mark negative controls without use of reverse 
transcriptase. The length (bp) of each PCR product is stated at the bottom of the picture. B. 
mRNA expression levels normalized to GAPDH expression level (number of experiments).  
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4.2 Protein expression of TMEM16 and LRRC8A as detected by 
immunoblotting 
As mRNA levels can significantly differ from the actual protein levels, we performed 
immunoblotting for TMEM16 and LRRC8A. As seen in figure 5, we could confirm the 
protein expression of TMEM16F, TMEM16K and LRRC8A in HeLa. We could also 
confirm that HeLa do not express TMEM16A. For this experiment we used the BHY 
cells as a positive control, as they were known from previous experiments to express 
TMEM16A abundantly. Further, we demonstrated that the RNA interference with 
siLRRC8A, siTMEM16F, siTMEM16K and si AQP3 was successful (Fig.5-6).  
 
Figure 5: A. Immunoblotting of LRRC8A in sicontrol and siLRRC8A treated HeLa cells. 
Complete suppression after RNA interference. B. Immunoblotting of siTMEM16K in sicontrol 
and siTMEM16K treated HeLa cells. Complete suppression of the TMEM16K expression. C. 
Immunoblotting of siTMEM16F in sicontrol and siTMEM16F treated HeLa cells. Significant 
suppression of TMEM16F expression. D. Immunoblotting of TMEM16A in HeLa and BHY 
cells under control conditions. HeLa do not express detectable levels of TMEM16A, in 
contrast to BHY cells.  
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Figure 6: A. Immunoblotting of AQP3 in HeLa cells after RNA interference with siAQP3, and 
control siRNA showing significant protein suppression. B. Immunoblotting of LRRC8A in 
sicontrol and siLRRC8A treated BHY cells, showing significant protein suppression. GAPDH 
was used as a positive control in all experiments. The molecular weight of the protein is 
marked in Kilodalton (kDa) at the left of each figure. 
4.3 RVD experiments 
4.3.1 RVD in HeLa cells under control conditions 
In the experiments depicted in figure 7 HeLa cells demonstrated a fast RVD after 
application of Ringer’s hypotonic 35% solution at the time point zero (t0). HeLa cells 
which were further kept in Ringer’s control solution maintained a constant volume 
through the time course of the experiment. This was the case in all following 
experiments, so that the volume curve for Ringer’s control solution will not be shown 
in following graphs. In order to compare the RVD efficiently among the several 
groups of inhibitors and after RNA interference and also independently of the initial 
volume in Ringer’s control solution (V0), the volume is depicted at any given time x 
(V) as a fraction to the initial volume (relative volume). In all further RVD experiments 
the cell volume will be shown as relative volume (normalized).  
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Figure 7: Volumetric response against time of HeLa cells exposed to Ringer’s hypotonic  
35% solution containing 0,4% DMSO v/v (closed circle) and Ringer’s control solution 0,4% 
DMSO v/v (open circles) at t0. A. Mean volume in fL. B. Relative volume (V/V0). Results given 
as mean volume ± SEM. (Number of experiments) 
 
All compounds used in this study were dissolved in DMSO. To rule out that the 
experimental results are due to the compound and not due to DMSO we used as a 
control group DMSO in a concentration not higher than 0,4% v/v. Addition of DMSO 
0,4% v/v in Ringer’s hypotonic 35% solution had no effect on the RVD compared to 
Ringer’s hypotonic 35% only (data not shown). HeLa cells swelled to a maximal 
relative volume of 1,254 ± 0,012. After 2,5’ the volume already reduced to 1,098 ± 
0,011. The time for the half maximal RVD was 2,194 ± 0,165 seconds (s). The 
relative volume RVD curve shown in Fig. 7 was fitted to the equation y = y0 + A
-R
0
x, 
where y0=0,989 ± 0,004, A=0,330 ± 0,007 and R0=0,448 ± 0,028 (adj. R-
Square=0,9989). 
4.3.2 RVD in LRRC8A deficient HeLa cells 
Knockdown of LRRC8A lead to slightly delayed RVD response induced by Ringer’s 
35% hypotonic solution (Fig. 8A). The relative volume at t=2,5’ was significantly 
higher in siLRRC8A compared to sicontrol (1,140 ± 0,019 vs. 1,074 ± 0,018) treated 
cells. The other criteria (R0 and the time for half maximal RVD) were not significantly 
different (Fig. 16-17, see experiments without Ba2+/TEA). We exchanged Ringer’s 
solution to Ringer’s isotonic solution (Table 3) and repeated the experiment. As seen 
in figure 8B, no significant difference could be observed between siLRRC8A and 
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sicontrol treated cells. The initial cell volume was found to be similar between control 
and siLRRC8A knockdown cells after incubation in control solution (Ringer’s, 
depicted in Fig. 9, or Ringer’s isotonic, data not shown) for 10 minutes. On the other 
hand, the initial cell volume (for both control and siLRRC8A knockdown cells) was 
significantly higher after incubation in Ringer’s solution (3108 ± 66 fL) than in Ringer’s 
isotonic solution containing mannitol (2702 ± 98 fL). 
Figure 8: RVD of siLRRC8A and sicontrol treated HeLa cells. A. Preincubation with Ringer’s 
before applying Ringer’s hypotonic 35%. The relative volume at t=2,5’ is significantly 
higher(#) in siLRRC8A compared to sicontrol. B. Preincubation with Ringer’s isotonic before 
applying Ringer’s hypotonic 35%. Results given as mean volume ± SEM. (Number of 
experiments)  
 
Figure 9: Initial volume at t=0 after 
incubation with Ringer’s solution. 
Depicted are data for LRRC8A, 
TMEM16F, TMEM16K and AQP3 
deficient cells and the respective 
sicontrol cells for each. Results 
given as mean volume ± SEM. 
(Number of experiments, common 
in all graphs). # significantly 
different from sicontrol cells. 
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4.3.3 RVD in LRRC8A deficient BHY cells  
In order to examine if the knockdown of LRRC8A has similar effects on other cell 
lines, we repeated the experiment in BHY cells using the protocol Ringer’s and 
Ringer’s hypotonic 35%. BHY cells exhibited a slower RVD than HeLa cells. For this 
reason the measurements were performed for 15 minutes instead of 10. As shown in 
figure 10, the difference in the RVD response of the siLRRC8A and sicontrol treated 
BHY cells is more obvious than the one of HeLa cells. The time for half maximal RVD 
is 2.92 ± 0.348 s in sicontrol vs. 7.413 ± 0.749 s in siLRRC8A and the R0 is 0.288 ± 
0.037 and 0.074 ± 0.015 respectively. The relative volume at t=2,5’ is not significantly 
different between the two groups, which is explained by the higher maximal volume 
of sicontrol and the ‘’flatter’’ curve of siLRRC8A cells. Consistent with this, the relative 
volume at later time points (t=3,5’-14,5’) is significantly different. 
 
 
Figure 10: Effect of LRRC8A knockdown on the RVD of BHY cells exposed to Ringer’s 
hypotonic 35%. A. Relative volume against time of siLRRC8A and sicontrol. B. # R0 is 
significantly higher in sicontrol than siLRRC8A. C. # Time for half maximal RVD in 
sicontrol is significantly shorter than for siLRRC8A. Results given as mean values ± 
SEM. (Number of experiments) Number of experiments is same for A.-C.  
4.3.4 RVD in TMEM16 deficient HeLa cells  
As LRRC8A does not evidently play a key role in the volume regulation of HeLa cells, 
the question emerged if the Cl- channels family of TMEM16 is involved. As seen in 
figure 4, HeLa express mainly TMEM16F and TMEM16K, so we performed the RVD 
experiments after knockout of those proteins. Neither knockdown of TMEM16F nor of 
TMEM16F had an effect on the RVD (Fig. 11). 
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Figure 11: A. Effect of TMEM16F knockdown on the RVD of HeLa cells under Ringer’s 
hypotonic 35% solution. B. Effect of TMEM16K knockdown on the RVD of HeLa cells under 
Ringer’s hypotonic 35% solution. Results given as mean volume ± SEM. (Number of 
experiments) 
 
4.3.5 RVD in AQP3 deficient HeLa cells  
AQPs are water channels. Knockdown of AQP3 has been shown to impair RVD in 
human intestine epithelial cells (Kida et al. 2005). In an attempt to recognize the 
mechanism responsible for RVD in HeLa cells, AQP3 was also knocked down in this 
cell line and the RVD experiment was repeated with Ringer’s and Ringer’s hypotonic 
35% solution. No significant change in the RVD was detected (Fig. 12).  
 
 
 
 
 
 
Figure 12: Relative volume against time 
of siAQP3 and sicontrol treated HeLa. 
Preincubation with Ringer’s before 
applying Ringer’s hypotonic 35% 
solution. Results given as mean volume 
± SEM. (Number of experiments). 
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4.3.6 RVD in HeLa after application of Cl- channels inhibitors  
As Cl- efflux is one of the mechanisms of RVD, several Cl- channels inhibitors were 
tested for their effect on RVD of HeLa cells. Tamoxifen and NS 3728 are both VRAC 
inhibitors, but  NS 3728 has been shown recently to block TMEM16 channels as well 
(Kunzelmann 2015). T16Ainh-A01 is a TMEM16 blocker.  
 
 
 
 
 
Tamoxifen 10 µM caused a slower RVD. Relative volume at t=2,5’ (1,243 ± 0,024 vs. 
1,098 ± 0,011), time for half maximal RVD (3,322 ± 0,180 vs. 2,194 ± 0,165 minutes) 
and R0 (0,203 ± 0,028 vs. R0=0,448 ± 0,028) were significantly different compared to 
DMSO treated cells. T16Ainh-A01 had no significant effect. NS 3728 treated cells 
showed a flatter RVD curve (R0=0,242 ± 0,016) compared to DMSO treated cells 
(R0=0,448 ± 0,028) (Fig. 13). 
Figure 13: Relative volume against time 
of inhibitor and DMSO treated HeLa 
cells. Preincubation with Ringer’s before 
applying Ringer’s hypotonic 35%. A. 
Tamoxifen 10 µM. # volume at t=2,5’, 
time for half maximal RVD and R0 
significantly different to DMSO. B. 
T16Ainh-A01 10 µM. C. NS 3728 10 µM. 
# R0 significantly different to DMSO. 
Results given as mean volume ± SEM. 
(Number of experiments) 
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4.3.7 RVD in HeLa after application of K+ channels inhibitors  
Ba2+ is a potent K+ channel inhibitor. TEA is a nonselective antagonist of big 
conductance K+ channels (BK). We performed the RVD experiments in LRRC8A, 
TMEM16F and TMEM16K deficient HeLa cells in the presence of 5 mM Ba2+ and 10 
mM TEA. Ba2+/TEA itself inhibited RVD significantly. The protein knockdown on the 
other hand showed no remarkable effect on the RVD under these conditions (Fig. 14, 
15). Figures 16 and 17 quantitatively demonstrate the effect of Ba2+/TEA on the 
criteria used to compare RVD. 
  
 
Figure 14: RVD in LRRC8A (A1) and TMEM16F (B1) deficient HeLa cells in the absence 
(A1, B1) and presence of Ba2+/TEA (A2, B2 respectively). Preincubation with Ringer’s before 
applying Ringer’s hypotonic 35%. Results given as mean volume ± SEM. (Number of 
experiments) 
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Figure 15: RVD in TMEM16K deficient HeLa cells in the absence (A1) and presence of 
Ba2+/TEA (A2). Preincubation with Ringer’s before applying Ringer’s hypotonic 35%. Results 
given as mean volume ± SEM. (Number of experiments) 
 
 
Figure 16: RVD of HeLa cells. A1. R0 in the absence of Ba
2+/TEA. A2. R0 in the presence of 
Ba2+/TEA. R0 significantly different (§) compared to absence of Ba
2+/TEA. Preincubation with 
Ringer’s (without or with Ba2+/ TEA) before applying Ringer’s hypotonic 35% (without or with 
Ba2+/TEA). Depicted are data for LRRC8A, TMEM16F and TMEM16K deficient cells and the 
respective sicontrol treated cells for each group. Results given as mean R0 ± SEM. (Number 
of experiments) 
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Figure 17: RVD of HeLa cells. A1. Relative volume at t=2,5’, in the absence of Ba2+/TEA. 
# siLRRC8A significantly different to scrambled. A2. Relative volume at t=2,5’ in the 
presence of Ba2+/TEA. § Relative volume significantly different compared to absence of 
Ba2+/TEA. B1. Time for half maximal RVD in the absence of Ba2+/TEA. B2. Time for half 
maximal RVD in the absence of Ba2+/TEA. § Time for half maximal RVD significantly different  
compared to absence of Ba2+/TEA. 
Preincubation with Ringer’s solution (without or with Ba2+/TEA) before applying Ringer’s 
hypotonic 35% (without or with Ba2+/TEA).  Depicted are data for LRRC8A, TMEM16F and 
TMEM16K deficient cells and the respective sicontrol treated cells for each group. Results 
given as mean values ± SEM. (Number of experiments is same as in figure 16) 
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On the contrary, application of the more selective SK3 inhibitor NS 8593 had no 
effect on the RVD of HeLa cells. Previous experiments have found SK3 channels to 
be volume sensitive only in hepatic and cholangiocarcinoma cells (Hoffmann et al. 
2009) (Fig. 18). 
 
 
 
4.3.8 RVD in HeLa after application of K+-Cl- cotransporter inhibitor 2 
Even though inhibition of Cl- and K+ channels in the previous experiments led to a 
prolonged RVD, the cells were still able to regulate their volume. In search of a 
mechanism which had a stronger impact on volume regulation we used the 
compound RDIOA to inhibit the KCC2. This had indeed a significant effect: a larger 
relative volume at t=2,5’ (1,218 ±0, 010 vs.1,098 ± 0,011), a longer time for half 
maximal RVD (3,675 ± 0,491 vs. 2,194 ± 0,165 minutes) and a smaller R0 (0,161 ± 
0,073 vs. 0,448 ± 0,028) compared to DMSO (Fig. 19A). In order to further impair the 
RVD response we applied RDIOA simultaneously to NS 3728. This succeeded to 
block the RVD in HeLa. The relative volume at t=2,5’ (1,208 ± 0,009 vs. 1,098 ± 
0,011) and the half maximal RVD (7,5 ± 0,866 vs. 2,194 ± 0,165 minutes) were 
significantly different compared to DMSO (Fig. 19B). R0 was not an appropriate 
criterion for such a flat curve, as it could not be fitted satisfactorily into the equation of 
exponential decrease. 
 
Figure 18: Relative volume against time 
of NS 8593 and DMSO treated HeLa 
cells. Preincubation with Ringer’s before 
applying Ringer’s hypotonic 35%. Results 
given as mean volume ± SEM. (Number 
of experiments).  
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Figure 19: Relative volume against time of inhibitor (closed circle) and DMSO treated (open 
circle) HeLa cells. Preincubation with Ringer’s before applying Ringer’s hypotonic 35%. A. 
RDIOA 50 µM. # Volume at t=2,5’, time for half maximal RVD and R0 significantly different to 
DMSO. B. RDIOA 50 µM + NS 3728 10 µM. # Volume at t=2,5’ and time for half maximal 
RVD significantly different to DMSO. Results given as mean volume ± SEM. (Number of 
experiments).  
 
4.3.9 RVD in HeLa after application of TRP channel and PI3K inhibitors 
As the complex mechanisms of RVD activation and regulation are still not clearly 
understood, we further investigated the impact of the pharmacological inhibition of 
the transient receptor potential (TRP) channels and the phosphatidylinositol-4,5-
bisphosphate 3-(PI3K) kinases. 
 
 
Figure 20: Relative volume against time of inhibitor and DMSO treated HeLa cells. 
Preincubation with Ringer’s before applying Ringer’s Hypo 35%. A. SKF 96365 20 µM. # 
Volume at t=2,5’, time for half maximal RVD and R0 significantly different to DMSO. B. 
Wortmannin 500 nM. # Volume at t=2,5’, time for half maximal RVD and R0 significantly 
different to DMSO. Results given as mean volume ± SEM. (Number of experiments).  
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SKF 96365 delayed RVD; the volume at t=2,5’ (1,230 ± 0,022vs.1,098 ± 0,011), the 
time for half maximal RVD ( 5,273 ± 0,109 vs. 2,194 ± 0,165 minutes) and the R0 
(0,025 ± 0,014 vs. 0,448 ± 0,028) were significantly different compared to DMSO 
(Fig. 20A). 
Wortmannin had a similar effect; the volume at t=2,5’ (1,218 ± 0,017 vs.1,098 ± 
0,011), the time for half maximal RVD (2,753 ± 0,249 vs. 2,194 ± 0,165 minutes) and 
the R0 (0,274 ± 0,034 vs. 0,448 ± 0,028) were also significantly different compared to 
DMSO (Fig.20B-21). 
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4.3.10 Summary of RVD parameters for inhibitor treated cells 
Volume at t=2,5’, R0, time for half maximal RVD, as well as initial volume at t=0 after 
incubation with Ringer’s control solution for 10 minutes can be seen in Fig. 21 for all  
compounds used.  
 
Figure 21: RVD in HeLa cells A. Initial volume at t=0 after incubation with Ringer’s control 
solution for 10 minutes. # significantly different from DMSO. B. R0. # significantly different 
from DMSO. C. Time for half maximal RVD. # significantly different from DMSO D. Relative 
volume at t=2,5’ (arbitrary units). # significantly different from DMSO. Results given as mean 
values ± SEM. (Number of experiments, common in all graphs).  
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4.3.11 RVD in HeLa after application of staurosporin  
VRAC has been linked to AVD and apoptosis. Application of staurosporin on 
scrambled siRNA treated HeLa cells for 6 hours lead to apoptotic shrinkage and 
massively compromised the acute RVD as compared to control cells. Practically, 
staurosporine treated cells no longer showed cell swelling (Fig. 22A). Knockdown of 
LRRC8A, TMEM16K and application of NS 3728 had no impact on the AVD, whereas 
the knockdown of TMEM16F and the application of RDIOA could limit cell shrinkage 
(Fig. 22B). 
 
 
 
Figure 22: A. Relative volume against time of DMSO and staurosporin treated HeLa cells. 
Preincubation with Ringer’s control solution before applying Ringer’s hypotonic 35%. Results 
given as mean volume ± SEM. B. Mean volume of sicontrol, siLRRC8A, siTMEM16A, 
siTMEM16F, siTMEM16K, NS 3728 10 µM and RDIOA 50 µM treated HeLa after application 
of DMSO or staurosporin (Number of experiments). Results given as mean volume ± SEM.  # 
Mean volume significantly lower after treatment with staurosporin compared to treatment with 
DMSO.  
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4.4 Apoptosis (Caspase 3) assays 
Initially it was essential to determine such a time point for the measurement of the 
caspase 3 activity,  that could show a significant difference in apoptosis rate between 
DMSO and staurosporin treated cells. This would then allow the detection of possible 
effects of the inhibitors and siRNA treatments. For this reason, the percentage of the 
green fluorescent (stained) apoptotic cells to the total of cells was measured every 
thirty minutes after incubation with caspase 3 substrate with staurosporin 1 µM or 
DMSO 0,5% v/v in Ringer’s solution for a total of six hours (Fig. 24A). An example of  
caspase 3 activation can be seen in fig. 23. 
  
Figure 23: Caspase 3 activity assay at the timepoints of 0 and 6 hours after treatment with 
DMSO or staurosporin. The green fluorescent cells represent apoptotic cells. 
 
As seen in figure 24A, there is a statistical significance between the rate of the 
apoptotic  cells of the staurosporin treated cells compared to the DMSO treated cells 
already at t=3,5 hours. At a time point much later than 6 hours the apoptosis induced 
detaching of a large number of glass. At this single time point the percentage of 
apoptotic cells after treatment with DMSO was 2,93 ± 0,47% and the percentage of 
apoptotic dead cells from the cover glass, which could not be counted, a fact which 
could lead to a biased result (experiment not showed). For these reasons it was 
deemed necessary to perform the subsequent caspase 3 experiments at the time 
point of 6 hours, when the difference was quite obvious, but apoptotic cells were still 
attached to the cover cells after staurosporin treatment was 22,17% ± 1,77%, which 
is a statistical significant difference (Fig. 24B). The percentage of the apoptotic cells 
is explicitly higher in this experiment (Fig. 24B) than in the time course experiment for 
both DMSO and staurosporin treated cells (Fig. 24A, time=6 hours). This could be 
explained by the exposure of the cover glasses at room temperature and low CO2 
during the time course experiment, when the microscope was used every thirty 
minutes, compared to the cover glasses of the single time point experiment, which 
were kept in the incubator for the whole six hours.  
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Figure 24: Staurosporin induces apoptosis in HeLa cells. A. Percentage of stained 
(apoptotic) cells to total cells plotted against time after applying caspase 3 substrate 
containing staurosporin or DMSO. For time=30 minutes to 4 hours: n experiments=4, n areas 
 12. For time= 4,5 - 6 hours: n experiments=1-4, n areas  3. The difference between 
DMSO and staurosporin treated cells is already statistically significant according to T-TEST 
(#) after t=3,5 hours. B. Percentage of the stained cells to total cells examined at a single 
time point 6 hours after the application of caspase 3 substrate containing DMSO or 
staurosporin. n experiments=2, n areas = 6. Percentage of apoptotic cells significantly 
different between staurosporin and DMSO group according to T-TEST(#).The percentage of 
apoptotic cells for the DMSO group, as well as for the staurosporin group, in experiment A 
(timepoint:6 hours) and B is statistically different according to T-TEST. Results given as 
mean values ± SEM. 
 
4.4.1 Induction of apoptosis in the presence of VRAC and KCC 
inhibitors  
As for RVD experiments, NS 3728 was used as a VRAC inhibitor and RDIOA was 
used as a KCC2 inhibitor. Goal of this experiment was to investigate whether 
preincubation with NS 3728 or RDIOA had an effect on staurosporin induced 
apoptosis, compared with preincubation with DMSO. For this reason the experiment 
was carried out in the groups of DMSO/ staurosporin, NS 3728/ staurosporin and 
RDIOA/ staurosporin. In order to investigate a possible effect of the inhibitors on 
apoptosis the control groups of DMSO/ DMSO, DMSO/ NS 3728 and DMSO/ RDIOA 
were used. The percentage of the apoptotic cells in the DMSO/ DMSO group was 
1,72 ± 0,31%, in the DMSO/ staurosporin group 21,26 ± 1,24%, in the NS 3728/ 
DMSO group 1,31 ± 0,24%, in the NS 3728/ staurosporin 21,27 ± 1,65%, in the 
RDIOA/ DMSO group 2,66 ± 0,58% and in the RDIOA/ staurosporin group 11,73 ± 
0,75%. The results are given as average values ± SEM calculated from the areas/ 
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group. As seen in figure 25, treatment with NS 3728 and RDIOA under control 
conditions with DMSO 0,5% v/v did not affect the apoptosis rate of the cells. 
Preincubation with NS 3728 10 µM for thirty minutes before applying staurosporin 
showed no effect on the apoptosis rate compared to the control group, where the 
cells were pretreated with DMSO 0,5% v/v. On the contrary, preincubation with 
RDIOA 50 µM significantly reduced caspase 3 activation.  
 
       
 
4.4.2 Induction of apoptosis in LRRC8A and TMEM16F deficient cells  
In order to further investigate the role of chloride channels in the AVD and apoptosis, 
a caspase 3 assay was performed in LRRC8A and TMEM16F deficient cells. The 
percentage of the dead cells for sicontrol was 21,35 ± 0,80%, for siTMEM16F 17,97 ± 
0,71% and for siLRRC8A 15,11 ± 0,72%. The results are given as average values ± 
SEM calculated from the areas/ group. As seen in figure 26, the knockdown of 
Figure 25: Percentage 
of the apoptotic/ total 
cells after treatment 
with caspase 3 
substrate and DMSO/ 
DMSO, DMSO/ 
staurosporin, NS 
3728/DMSO, NS3728/ 
staurosporin, RDIOA/ 
DMSO and RDIOA/ 
staurosporin. # The 
RDIOA/ staurosporin 
treated cells showed a 
significantly lower 
apoptosis rate to the 
control group of DMSO/ 
staurosporin treated 
cells. 4-9 cover glasses 
with a total of 15-40 
areas were used/ 
group. 223-663 cells 
were examined/ cover 
glass. Results given as 
mean values ±SEM. 
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TMEM16F and LRRC8A had a statistically significant effect on the caspase 3 
activation compared to treatment with control siRNA. 
 
4.5 Proliferation assays in LRRC8A deficient HeLa cells and in the presence 
of VRAC inhibitors  
Given the role of VRAC in apoptosis, it was interesting to examine the proliferation of 
cells under LRRC8A knockdown and pharmacological inhibition of VRAC. As seen in 
figure 27, knockdown of LRRRC8A had no effect on the proliferation of HeLa cells 
within seven days. Application of T16Ainh-A01 10 µM also did not influence the cell 
numbers. Tamoxifen 1 µM had no significant impact on the cell proliferation. On the 
contrary, an augmented dose of tamoxifen (10 µM) inhibited proliferation significantly 
from day 2 to day 7 (Fig. 28).  
 
Figure 26:  Percentage of the apoptotic/ 
total cells after treatment with caspase 3 
substrate and staurosporin in sicontrol, 
siTMEM16F and siLRRC8A HeLa cells. 
Results given as mean values ±SEM. The 
siTMEM16F and siLRRC8A treated cells 
both showed a significantly lower 
apoptosis rate (#) compared to sicontrol. 
9-18 cover glasses with a total of 38-67 
areas were used/ group. 44-762 cells 
were examined/ cover glass.  
 
 
Fig. 27: Viable cells/ well 
over seven days in 
sicontrol and siLRRC8A 
HeLa. Results given as 
mean values ± SEM. 
(Number of experiments). 
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Fig. 28: Viable cells/ well 
over seven days in 
presence of DMSO 0,1% 
v/v,  T16Ainh-A01 10 µM, 
tamoxifen 1 µM and 
tamoxifen 10 µM. Results 
given as mean values ± 
SEM. (Number of 
experiments). # Under 
tamoxifen 10 µM 
significantly different cell 
numbers from day 2 to 
day 7. 
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5. Discussion 
VRAC is crucial for RVD and apoptosis. With its molecular identity being unknown for 
almost thirty years, several proteins have been proposed as candidates. Lately 
LRRC8A has been recognized as an essential component of the VRAC (Qiu et al. 
2014; Voss et al. 2014). The main objective of this study was to examine whether 
LRRC8A is indispensable for volume regulation. The results of the present work 
suggest that LRRC8A plays a subsidiary role in RVD of HeLa cells. Flow cytometry 
experiments in sicontrol HeLa cells demonstrated a completion of the RVD within 5 
minutes (Fig.7). After LRRC8A knockdown the RVD was slightly delayed, but was 
nevertheless completed in a time frame of ten minutes (Fig. 8). 
 
On the contrary, Qiu et al. reported a restoration of cell volume in sicontrol HeLa cells 
within 20 minutes after the application of hypotonic solution. As to siLRRC8A 
deficient cells, the relative cell volume was still enlarged up to 1,2 even after 10 
minutes. In the experiments of Voss et al. sicontrol human embryonic kidney 293 
(HEK) cells did not return to their initial volume even after 60 minutes in hypotonic 
solution. This is surprising, given that RVD should be quick in order to maintain the 
fragile cell homeostasis. LRRC8A deficient HEK cells exhibited a total abolition of 
RVD; relative volume continued to increase even one hour after application of 
hypotonic solution. 
 
One possible explanation for the inconsistency of these data is the temperature, at 
which the RVD experiments were performed. The RVD experiments presented here 
were carried out at 37°C, whereas the experiments in the two papers mentioned 
above were carried out at room temperature. The channel and transporter activity are 
both temperature dependent, but energy dependent transporters are more 
susceptible to low temperature. Low temperature abolished the contribution of KCC 
to RVD in glia cells, but not the one of Cl- channels (Ernest et al. 2005). Furthermore, 
there are remarkable variations among HeLa cells due to occurring mutations in 
consequence of the very long time that those cells have been in culture (Sun et al. 
2015). Passage, cell culture conditions and type may lead to unexpected differences. 
Transfection is also a factor of variance, with off-target effects being possible. In the 
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present study one type of siLRRC8A was used, leading to a complete elimination of 
the protein expression, as proven by immunoblotting (Fig. 5A). In both other studies 
three and four different pooled siRNAs were used.  
 
In addition, the composition of the isotonic and hypotonic solutions is not 
unimportant. When developing a protocol for RVD, a major question is how to change 
only one parameter each time (mediaisotonic solutionhypotonic solution), so that 
the subsequent changes can be clearly attributed to this single change. A common 
method to create an isotonic and an hypotonic solution for RVD experiments is to use 
a particular ionic concentration with osmolality lower than 280 mOsm/kg (hypotonic 
solution) and then add mannitol until an osmolality of 280 mOsm/kg (isotonic 
solution) is reached. The advantage of this method is that both solutions contain the 
same ions in the same concentration and only differ in osmolality. This is the reason 
that this protocol has been broadly used in RVD studies. In this case though, there is 
a difference in the ionic concentration of Cl- in the culture medium and the isotonic 
solution (145 mmol vs. 95 mmol/ L) (Table 3). The reduced extracellular Cl- 
concentration causes VRAC activation, as shown by patch clamp recordings of our 
group, and leads to Cl- loss, cell shrinkage and a less pronounced cell swelling after 
application of hypotonic solution. Using this protocol no significant difference was 
observed in the RVD between LRRC8A deficient and sicontrol HeLa cells (Fig. 8B).  
 
In order to avoid VRAC activation under control conditions we modified the protocol 
using Ringer’s solution without mannitol as a control solution (Cl- concentration: 145 
mmol/ L) (Fig. 29) (Table 3). Under these conditions LRRC8A knockdown lead to a 
slightly delayed RVD (Fig. 8A). The RVD experiments in BHY cells showed a delayed 
RVD after LRRC8A knockdown, an effect more pronounced than in HeLa cells (Fig. 
10). This is puzzling, given the similar level of the protein expression in 
immunoblotting (Fig. 5A, 6B). Given that the LRRC8A is an essential component of 
the VRAC, obviously there are more factors involved in the RVD and the contribution 
of LRRC8A to RVD in individual cells is rather variable. 
 
TMEM16 are involved in volume regulation and they had been proposed as VRAC 
candidates in the past (Sirianant et al. 2015; Almaça et al. 2009). In the current series 
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of experiments HeLa cells do not express TMEM16A and knockdown of TMEM16F 
and TMEM16K showed no effect on the RVD (Fig. 11). 
 
 
 
Fig. 29: RVD under two different protocols. Above, using Ringer’s isotonic with mannitol as a 
control solution leads to Cl- loss in the extracellular space and cell shrinkage. Below, using 
Ringer’s without mannitol and more physiological NaCl concentration, this effect is being 
avoided. 
  
In previous studies inactivation of TMEM16A in HEK cells has been linked with 
reduction of the LRRC8A dependent Cl- current (Sirianant et al. 2014), whereas mice 
lacking TMEM16A showed impaired ICl(swell) (Almaça et al. 2009). LRRC8A 
knockdown had a bigger effect on the RVD in BHY cells, which express TMEM16A 
abundantly, than in HeLa, which do not express TMEM16A, despite similar levels of 
LRRC8A expression. The arising question, whether LRRC8A is functionally linked to 
TMEM16A, should be further investigated in the future. 
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Even though LRRC8A plays a role in RVD in HeLa cells, volume regulation is still 
possible after knockdown of LRRC8A, as well as after VRAC inhibition with tamoxifen 
and NS 3728 (Fig. 13). In comparison, RVD was more attenuated after inhibition of 
K+-channels and KCC2. Ba2+/TEA slowed RVD down, whereas the simultaneous 
knockdown of LRRC8A, TMEM16F and TMEM16K had no additive effect. RDIOA 
suppressed RVD effectively, suggesting that KCC2 plays a role in the RVD of HeLa 
cells. The role of KCC for RVD in other cells types, e.g. red blood cells has been 
demonstrated before (Adragna et al. 2015). In accordance to this, loss of KCC 
function in cervical cancer cells inhibited cell growth and cancer invasion by impairing 
volume regulation (Shen et al. 2003). Simultaneous application of RDIOA and NS 
3728 had the most pronounced effect.  
 
Even though the VRAC properties have been extensively described, the mechanism 
of VRAC activation after osmotic swelling is not yet clear. Changes in the intracellular 
osmolarity have been confirmed as an activating factor, but numerous other 
mechanisms have been suggested to play a role, for example phospholipase A2, 
reactive oxygen species (ROS) and intracellular adenosine triphosphate (ATP) and 
Ca2+ concentration (Kunzelmann 2015). Transient receptor potential (TRP) channels, 
which serve as sensors for various physical and chemical stimuli, have also been 
shown to contribute to RVD, by augmenting intracellular Ca2+, which then activates 
Ca2+-sensitive K+ and Cl- channels (Sirianant et al. 2015; Hoffmann und Lambert 
2014). Consistent to those data, the TRP channel inhibitor SKF 96365 attenuated 
RVD in HeLa (Fig. 20A). The PI3K pathway has been also reported to be involved in 
RVD through mediating taurine efflux (Franco et al. 2004). Its inhibition leads to 
impaired volume regulation in cardiomyocytes (Wadey et al. 2010). PI3K inhibitor 
wortmannin also impaired RVD in HeLa (Fig. 20B). As both inhibitors are not 
perfectly selective, further experiments are necessary to evaluate the role of PI3K 
and TRP channels in RVD of HeLa. 
 
The involvement of VRAC in the induction of AVD has been well established (Okada 
et al. 2006; Okada et al. 2004). Under staurosporin HeLa cells exhibited AVD, cell 
shrinkage and impaired RVD (Fig. 22). Knockdown of LRRC8A had no impact on the 
proliferation, but could reduce the apoptosis rate after staurosporin. This is consistent 
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with LRRC8A being an essential component of VRAC. Surprisingly, VRAC inhibition 
with NS 3728 failed to inhibit both staurosporin induced AVD and caspase activation, 
a finding which does not agree with previous data (Hoffmann und Lambert 2014). Off 
target effects of RNA interference or chemical side effects could offer a possible 
explanation. NS3728 belongs to the relative new group of Cl- conductance inhibitors 
of acidic di-aryl ureas, being the most potent of them (Hélix et al. 2003).The structural 
inhomogenity of the substances that can inhibit VRAC (traditionally: DIDS, niflumic 
acid, NPPB, tamoxifen and the group of the acidic di-aryl ureas) raise the suspicion 
that some of these may act by interfering on various levels of the VRAC activation 
and not directly with the channel (Hélix et al. 2003).  
 
Staurosporin has been shown to activate KCC in erythrocytes (Bize und Dunham 
1994). Inhibition of KCC2 with RDIOA could reduce both AVD (Fig. 22) and caspase 
activation (Fig. 25), to an extent larger than LRRC8A knockdown (Fig.26), implying a 
role for KCC in AVD in HeLa cells. In previous experiments similar doses of RDIOA 
did not reduce DNA laddering after staurosporin treatment in HeLa (Okada et al. 
2004). This discrepancy could be due to the different methods used. TMEM16F 
knockdown could also diminish AVD and caspase activation in HeLa cells, confirming 
its role in apoptosis (Kmit et al. 2013), whereas it had no effect on the RVD. 
 
The LRRC8A gene was first detected in a patient with agammaglobulinemia, lack of 
B-lymphocytes and minor facial abnormalities which expressed a mutated LRRC8A 
product along with the normal protein (Sawada et al. 2003). Depletion of the gene in 
mice lead to increased pre- and postnatal mortality and T-cell dysfunction (Kumar et 
al. 2014). LRRC8A being an essential VRAC component implies that loss of LRRC8A 
would have a significant impact on volume regulation, possibly causing a more 
dramatic phenotype in those animals. 
 
A recent publication claimed that in human retinal pigment epithelial (RPE) cells and 
in murine sperm cells LRRC8A does not play a role in volume regulation (Milenkovic 
et al. 2015). The key player in RVD in these tissues was shown to be bestrophin 1 
(BEST 1), belonging to a protein family of four paralogues. Human RPE cell lines 
expressing a mutated BEST1 showed a much smaller ICl(swell) compared to the control 
cell line. Knockdown of LRRC8A in the control cell line had no effect on the ICl(swell) 
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(Milenkovic et al. 2015). Functional disruption of BEST 1 causes retinal macular 
dystrophy in humans and infertility in mice, possibly as a result of the impaired 
volume regulation. 
 
In conclusion, LRRC8A plays a role for the RVD of HeLa cells, but volume regulation 
is still possible without it. LRRC8A contributes to varying degrees to volume 
regulation among cell types, whereas it does not seem to be involved in AVD. Future 
research is necessary before LRRC8A could be introduced as a possible 
pharmacological target. 
There are still a lot of aspects which need to be elucidated: 
 Do LRRC8A polymers actually form the channel pore? 
 How is LRRC8A activated and regulated in detail? 
 Are TMEM16 proteins involved? 
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6. Summary  
Volume regulation is a crucial property of all living cells and it contributes to several 
physiological and pathological procedures. The volume regulated anion channel 
(VRAC) is involved in volume regulation, more specifically in regulatory volume 
decrease (RVD), and in volume decrease during apoptosis (apoptotic volume 
decrease, AVD). The protein LRRC8A (leucin rich repeat protein 8A) has been 
recently identified as an essential component of VRAC.  
 
In the present study the role of LRRC8A in RVD of HeLa cells could be confirmed 
using flow cytometry methods. On the other hand, LRRC8A knockdown and 
pharmacological VRAC inhibition did delay, but did not abolish RVD, showing that 
other mechanisms, as K+-Cl- cotransporters (KCC), play an important role in RVD. In 
spite of its universal expression, LRRC8A contributes to a various extent to the RVD 
among cell types. A further goal of this study was to examine whether Ca2+ activated 
chloride channels of the TMEM16 family are involved in RVD. The knockdown of 
TMEM16F and TMEM16K did not have a direct effect on the RVD of HeLa cells.  
 
HeLa proliferation was not dependent on the presence of LRRC8A. Furthermore, 
AVD could not be inhibited by LRRC8A knockdown or application of VRAC inhibitors. 
On the contrary, the present data suggest a role for KCC and TMEM16F in AVD. 
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